Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

February 28, 2017

Conditions
Treatment Resistant Depression
Interventions
DRUG

Ketamine

Dose of Ketamine will be 0.1 mg/kg - one single infusion

DRUG

Ketamine

Dose of Ketamine will be 0.2 mg/kg - one single infusion

DRUG

Ketamine

Dose of Ketamine will be 0.5 mg/kg - one single infusion

DRUG

Ketamine

Dose of Ketamine will be 1.0 mg/kg - one single infusion

DRUG

Placebo Midazolam

Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion

Trial Locations (6)

10029

Mount Sinai School of Medicine, New York

75390

University of Texas Southwestern, Dallas

77030

Baylor College of Medicine, Houston

94304

Stanford University, Palo Alto

06520

Yale University, New Haven

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Baylor College of Medicine

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

Stanford University

OTHER

collaborator

University of Texas

OTHER

collaborator

Yale University

OTHER

lead

Massachusetts General Hospital

OTHER

NCT01920555 - Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) | Biotech Hunter | Biotech Hunter